Haleos Labs Approves Q2 Financial Results; Announces Director Re-appointments and AGM Date
Haleos Labs Limited, specializing in the manufacturing of Active Pharmaceutical Ingredients and their intermediates, reported its unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The company also announced key governance decisions following a Board meeting held on August 5, 2026.The Board of Directors considered and approved the financial results for the quarter. Additionally, the board addressed matters including the re-appointment of Independent Directors and the revision of managerial remuneration.
Corporate Governance Updates
During the Board Meeting, several significant decisions were ratified:- Director Re-appointment: Two independent directors were re-appointed for a second term of five years, effective from November 13, 2026, pending shareholder approval. The appointed individuals are Dr. (Mr.) Mannam Malakondaiah and Dr. (Mr.) Srinivas Samavedam.
- Remuneration Review: The Board reviewed the managerial remuneration payable to Mr. TVVSN Murthy, Managing Director of the Company, subject to shareholders' approval.
- Annual General Meeting: The 20th Annual General Meeting has been scheduled for Wednesday, September 30, 2026, and will be conducted via Video Conferencing (VC) or other Audio Visual Means (OAVM).
Q2 FY26 Financial Performance
The company provided detailed financial results for the quarter ended June 30, 2026.Standalone Results (Qended June 30, 2026)
| Particulars | Amount (Rs. in Lakhs) |
|---|---|
| Revenue From Operations | 6,782.97 |
| Total Revenue | 6,828.58 |
| Total Expenses | 6,300.99 |
| Profit Before Tax (PBT) | 527.59 |
| Net Profit for the Period | 323.78 |
| Earnings Per Equity Share (Basic) | 10.71 |
Consolidated Results (Qended June 30, 2026)
| Particulars | Amount (Rs. in Lakhs) |
|---|---|
| Revenue From Operations | 7,294.23 |
| Total Revenue | 7,340.56 |
| Total Expenses | 6,996.59 |
| Profit Before Tax (PBT) | 343.97 |
| Net Profit attributable to Equity holders | 184.03 |
| Earnings Per Equity Share (Basic) | 8.75 |
Audit and Reporting
The unaudited financial results for both the standalone entity and the consolidated group have been reviewed by statutory auditors, who expressed an unmodified opinion on the statements in accordance with applicable accounting standards.The company's operations involve the manufacturing of Active Pharmaceutical Ingredients and their intermediates. The Board’s meeting commenced at 12:30 pm and concluded at 1:45 pm.
HALEOSLABS Stock Price Movement
As of 2:58 PM, HALEOS LABS LIMITED sheds value in live trading, dipping by 6.98% to trade at ₹1432.1, which represents a decline of ₹107.50. The stock has seen a total traded volume of 1,386 shares so far today, maintaining support above the intraday low of ₹1400.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.